{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:06:15Z","timestamp":1794549975668,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recipient\u2013donor chimerism is routinely analyzed after allogeneic hematopoietic stem cell transplantation (HSCT) to monitor engraftment and graft rejection. For malignancies, chimerism can also be used to screen for disease relapse post-HSCT but methodology and interpretation of results are not standardized and likely depend on underlying diagnosis. We have implemented highly sensitive and accurate methodologies for chimerism analysis for the purpose of improving relapse prediction. Here, we report an exploratory retrospective analysis of clinical routine chimerism results from all 154 HSCTs for acute myeloid leukemia (AML) performed at our center during the years 2015\u20132020 with the aim of suggesting a clinically useful threshold at which risk of relapse is high. Relapse was not reliably predicted based on single elevated chimerism values obtained before time of overt relapse. However, early complete donor chimerism, here defined as recipient DNA\u2009&lt;\u20090.2% in CD33<jats:sup>+<\/jats:sup> cells in any blood or bone marrow sample taken during the first 60 days after HSCT, correlated inversely with relapse during the observation time (log-rank test <jats:italic>P<\/jats:italic>\u2009=\u20090.033). We propose that achievement of complete chimerism determined early after HSCT using sensitive methods can be used for risk-stratification of AML patients.<\/jats:p>","DOI":"10.1038\/s41409-022-01615-8","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T18:04:39Z","timestamp":1645725879000},"page":"753-759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4447-9426","authenticated-orcid":false,"given":"Hannes","family":"Lindahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Vonlanthen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas T.","family":"Bj\u00f6rklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9871-0961","authenticated-orcid":false,"given":"Mikael","family":"Sundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8325-9215","authenticated-orcid":false,"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Hauzenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"1615_CR1","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/bmt.2016.20","volume":"51","author":"JR Passweg","year":"2016","unstructured":"Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transpl. 2016;51:786\u201392.","journal-title":"Bone Marrow Transpl"},{"key":"1615_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41409-018-0286-2","volume":"54","author":"CJ Lee","year":"2019","unstructured":"Lee CJ, Savani BN, Mohty M, Gorin NC, Labopin M, Ruggeri A, et al. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2019;54:519\u2013530.","journal-title":"Bone Marrow Transpl"},{"key":"1615_CR3","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610\u20131.","journal-title":"Bone Marrow Transpl"},{"key":"1615_CR4","doi-asserted-by":"publisher","first-page":"6475","DOI":"10.1158\/1078-0432.CCR-20-3134","volume":"26","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Schmid C, Labopin M, Beelen D, Wolfgang Blau I, Potter V, et al. Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years. Clin Cancer Res. 2020;26:6475\u20136482.","journal-title":"Clin Cancer Res"},{"key":"1615_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/leu.2011.234","volume":"26","author":"U Platzbecker","year":"2012","unstructured":"Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26:381\u20139.","journal-title":"Leukemia"},{"key":"1615_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00277-017-3185-5","volume":"97","author":"T Schroeder","year":"2018","unstructured":"Schroeder T, Rautenberg C, Kr\u00fcger W, Platzbecker U, Bug G, Steinmann J, et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol. 2018;97:335\u2013342.","journal-title":"Ann Hematol"},{"key":"1615_CR7","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N. Engl J Med. 2019;381:1728\u20131740.","journal-title":"N. Engl J Med"},{"key":"1615_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14:73.","journal-title":"J Hematol Oncol"},{"key":"1615_CR9","doi-asserted-by":"publisher","first-page":"100673","DOI":"10.1016\/j.blre.2020.100673","volume":"44","author":"AK Haugaard","year":"2020","unstructured":"Haugaard AK, Kofoed J, Masmas TN, Madsen HO, Marquart HV, Heilmann C, et al. Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature. Blood Rev. 2020;44:100673.","journal-title":"Blood Rev"},{"key":"1615_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/bjh.14778","volume":"179","author":"X-D Mo","year":"2017","unstructured":"Mo X-D, Lv M, Huang X-J. Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention. Br J Haematol. 2017;179:184\u2013197.","journal-title":"Br J Haematol"},{"key":"1615_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.path.2019.03.009","volume":"12","author":"W Xiao","year":"2019","unstructured":"Xiao W, Petrova-Drus K, Roshal M. Optimal measurable residual disease testing for acute myeloid leukemia. Surg Pathol Clin. 2019;12:671\u2013686.","journal-title":"Surg Pathol Clin"},{"key":"1615_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/MOH.0000000000000113","volume":"22","author":"Y Ofran","year":"2015","unstructured":"Ofran Y, Rowe JM. Introducing minimal residual disease in acute myeloid leukemia. Curr Opin Hematol. 2015;22:139\u201345.","journal-title":"Curr Opin Hematol"},{"key":"1615_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/bbmt.2001.v7.pm11669214","volume":"7","author":"JH Antin","year":"2001","unstructured":"Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood an. Biol Blood Marrow Transpl. 2001;7:473\u201385.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1615_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/bjh.13073","volume":"168","author":"JR Clark","year":"2015","unstructured":"Clark JR, Scott SD, Jack AL, Lee H, Mason J, Carter GI, et al. Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service. Br J Haematol. 2015;168:26\u201337.","journal-title":"Br J Haematol"},{"key":"1615_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/sj.leu.2401953","volume":"15","author":"C Thiede","year":"2001","unstructured":"Thiede C, Bornh\u00e4user M, Oelschl\u00e4gel U, Brendel C, Leo R, Daxberger H, et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia. 2001;15:293\u2013302.","journal-title":"Leukemia"},{"key":"1615_CR16","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/s41409-018-0176-7","volume":"53","author":"L Sellmann","year":"2018","unstructured":"Sellmann L, Rabe K, B\u00fcnting I, Dammann E, G\u00f6hring G, Ganser A, et al. Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation. Bone Marrow Transpl. 2018;53:1457\u20131465.","journal-title":"Bone Marrow Transpl"},{"key":"1615_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/bmt.2014.254","volume":"50","author":"N Jacque","year":"2015","unstructured":"Jacque N, Nguyen S, Golmard J-L, Uzunov M, Garnier A, Leblond V, et al. Chimerism analysis in peripheral blood using indel quantitative real-time PCR is a useful tool to predict post-transplant relapse in acute leukemia. Bone Marrow Transpl. 2015;50:259\u201365.","journal-title":"Bone Marrow Transpl"},{"key":"1615_CR18","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1182\/blood.V99.12.4618","volume":"99","author":"M Alizadeh","year":"2002","unstructured":"Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C, et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood. 2002;99:4618\u201325.","journal-title":"Blood"},{"key":"1615_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cca.2020.10.034","volume":"512","author":"L Pettersson","year":"2021","unstructured":"Pettersson L, Vezzi F, Vonlanthen S, Alwegren K, Hedrum A, Hauzenberger D. Development and performance of a next generation sequencing (NGS) assay for monitoring of mixed chimerism. Clin Chim Acta. 2021;512:40\u201348.","journal-title":"Clin Chim Acta"},{"key":"1615_CR20","doi-asserted-by":"publisher","first-page":"89.e1","DOI":"10.1016\/j.bbmt.2020.09.023","volume":"27","author":"P Pedini","year":"2021","unstructured":"Pedini P, Cherouat N, Basire A, Simon S, Budon L, Pourtein M, et al. Evaluation of next-generation sequencing and crystal digital PCR for chimerism monitoring of post-allogeneic hematopoietic stem cell transplantation. Transpl Cell Ther. 2021;27:89.e1\u201389.e10.","journal-title":"Transpl Cell Ther"},{"key":"1615_CR21","doi-asserted-by":"publisher","first-page":"e13549","DOI":"10.1111\/petr.13549","volume":"23","author":"AK Haugaard","year":"2019","unstructured":"Haugaard AK, Madsen HO, Marquart HV, Rosth\u00f8j S, Masmas TN, Heilmann C, et al. Highly sensitive chimerism detection in blood is associated with increased risk of relapse after allogeneic hematopoietic cell transplantation in childhood leukemia. Pediatr Transpl. 2019;23:e13549.","journal-title":"Pediatr Transpl"},{"key":"1615_CR22","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1615_CR23","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41409-018-0171-z","volume":"53","author":"M Horowitz","year":"2018","unstructured":"Horowitz M, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C, et al. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transpl. 2018;53:1379\u20131389.","journal-title":"Bone Marrow Transpl"},{"key":"1615_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/sj.bmt.1705582","volume":"39","author":"C Huisman","year":"2007","unstructured":"Huisman C, de Weger RA, de Vries L, Tilanus MGJ, Verdonck LF. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transpl. 2007;39:285\u201391.","journal-title":"Bone Marrow Transpl"},{"key":"1615_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/sj.bmt.1701119","volume":"21","author":"P Bader","year":"1998","unstructured":"Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R, et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transpl. 1998;21:487\u201395.","journal-title":"Bone Marrow Transpl"},{"key":"1615_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000077555","volume":"112","author":"C Thiede","year":"2004","unstructured":"Thiede C, Bornh\u00e4user M, Ehninger G. Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation. Acta Haematol. 2004;112:16\u201323.","journal-title":"Acta Haematol"},{"key":"1615_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/sj.bmt.1705938","volume":"41","author":"J Stumph","year":"2008","unstructured":"Stumph J, Vnencak-Jones CL, Koyama T, Frangoul H. Comparison of peripheral blood and bone marrow samples for detection of post transplant mixed chimerism. Bone Marrow Transpl. 2008;41:589\u201390.","journal-title":"Bone Marrow Transpl"},{"key":"1615_CR28","first-page":"1952","volume":"125","author":"X-Y Qin","year":"2012","unstructured":"Qin X-Y, Li G-X, Qin Y-Z, Wang Y, Wang F-R, Liu D-H, et al. Quantitative chimerism kinetics in relapsed leukemia patients after allogeneic hematopoietic stem cell transplantation. Chin Med J (Engl). 2012;125:1952\u20139.","journal-title":"Chin Med J (Engl)"},{"key":"1615_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1515\/cclm-2018-0827","volume":"57","author":"M Waterhouse","year":"2019","unstructured":"Waterhouse M, Pfeifer D, Duque-Afonso J, Follo M, Duyster J, Depner M, et al. Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation. Clin Chem Lab Med. 2019;57:641\u2013647.","journal-title":"Clin Chem Lab Med"},{"key":"1615_CR30","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.bbmt.2008.07.013","volume":"14","author":"B Saito","year":"2008","unstructured":"Saito B, Fukuda T, Yokoyama H, Kurosawa S, Takahashi T, Fuji S, et al. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen. Biol Blood Marrow Transpl. 2008;14:1148\u20131155.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1615_CR31","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ajh.24663","volume":"92","author":"M Jentzsch","year":"2017","unstructured":"Jentzsch M, Bill M, Nicolet D, Leiblein S, Schubert K, Pless M, et al. Prognostic impact of the CD34+\/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. Am J Hematol. 2017;92:388\u2013396.","journal-title":"Am J Hematol"},{"key":"1615_CR32","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/labmed\/lmz069","volume":"51","author":"J Philip","year":"2020","unstructured":"Philip J, Bajaj AK, Sharma S, Kushwaha N, Kumar S, Kumar Biswas A. Allogeneic peripheral blood stem cell transplant: correlation of donor factors with yield, engraftment, chimerism, and outcome: retrospective review of a single institute during a 3-year period. Lab Med. 2020;51:362\u2013369.","journal-title":"Lab Med"},{"key":"1615_CR33","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/sj.bmt.1705352","volume":"37","author":"Y Miura","year":"2006","unstructured":"Miura Y, Tanaka J, Toubai T, Tsutsumi Y, Kato N, Hirate D, et al. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation. Bone Marrow Transpl. 2006;37:837\u201343.","journal-title":"Bone Marrow Transpl"},{"key":"1615_CR34","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.exphem.2010.08.006","volume":"38","author":"B Wiedemann","year":"2010","unstructured":"Wiedemann B, Klyuchnikov E, Kr\u00f6ger N, Zabelina T, Stahl T, Zeschke S, et al. Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia. Exp Hematol. 2010;38:1261\u201371.","journal-title":"Exp Hematol"},{"key":"1615_CR35","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.bbmt.2014.05.025","volume":"20","author":"J Koreth","year":"2014","unstructured":"Koreth J, Kim HT, Nikiforow S, Milford EL, Armand P, Cutler C, et al. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transpl. 2014;20:1516\u201321.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01615-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01615-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01615-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T14:04:57Z","timestamp":1652191497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01615-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01615-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"assertion":[{"value":"15 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dan Hauzenberger is founder and co-owner of Devyser AB. He is also part-time employed by the company. Stephan Mielke has received speakers fee from Novartis and DNA Prime SA, has received travel support from and served in expert panel for Gilead\/KITE, has received travel support and speakers fee from Celgene\/BMS, has received research funding, travel support, and speakers fee from Kiadis Pharma, has served in expert panel for Bellicum, has received travel support and speakers fee from and has served in data safety monitoring board for Miltenyi, and has served in data safety monitoring board for Immunicum.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}